ReviewEndocrine connections2025
PERSPECTIVE: Treatment with hydrocortisone modified-release capsules in children and adolescents with congenital adrenal hyperplasia: an expert opinion.
Review in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Congenital Adrenal Hyperplasia in the Mediterranean: A Concise Overview.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modified-release hydrocortisone (EfmodyFrontiers in endocrinology · 2026Article
- Current insights into monitoring of congenital adrenal hyperplasia.Frontiers in endocrinology · 2026Review
- Integration of Adjunctive Therapy for Congenital Adrenal Hyperplasia.Children (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recommended treatment for classic congenital adrenal hyperplasia (CAH) in children is hydrocortisone. This therapy is intended to replace cortisol deficiency, but also to reduce the increased production of androgens and their precursors. The aim is to minimize the undesirable side effects of both cortisol deficiency and androgen excess. Short-acting conventional immediate-release hydrocortisone formulations does not mimic physiological diurnal rhythm and often complicate therapy adjustment, mandating frequent administration of often supraphysiological doses, typically 3-4 times daily, including nocturnal dosing. To simulate the physiological diurnal cortisol pattern, a delayed- and sustained-release hydrocortisone preparation has been developed and its efficacy was validated through phase 2 and 3 trials in adult patients. Regulatory approval has been extended to encompass both adult and adolescent patients aged 12 years and older. This manuscript aims to provide treatment principles formulated by two expert centers specialized in pediatric CAH therapy regarding the utilization of recently registered hydrocortisone modified-release capsules in the daily management and stress dosing regimen for adolescents with CAH. It elucidates proposed dosing strategies, therapeutic surveillance protocols and the prospective accumulation of data for the assessment of treatment efficacy during childhood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.